THE ANDHRA SUGARS LIMITED

Venkatarayapuram : Tanuku - 534 215, Andhra Pradesh, India.

SEC/2024

November 02, 2024.

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No.C/1
G. Block, Bandra Kurla Complex
Bandra (E)
MUMBAI – 400 051.

Dear Sirs / Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 – Reg.

* * * *

With reference to the above subject, we would like to inform you that our Aspirin Manufacturing Facility at Venkatarayapuram, Tanuku FEI 3003789475 have been inspected by USFDA from 09.09.2024 to 13.09.2024 and vide their E-Mail dt. 01.11.2024, USFDA have confirmed that the Facility is considered to be in an acceptable state of compliance with regard to the Current Good Manufacturing Practice (CGMP).

This is for your information and E-Mail received from USFDA is enclosed.

Thanking you,

P.V.S VISWANADHA KUMAR

Yours faithfully
For THE ANDHRA SUGARS LTD.,

(P.V.S. VISWANADHA KUMAR)
Vice President (Fin.) & Addl. Secretary

059688

Phone : +91-8819-224911 to 917,
Mobile:+91-8186828888, 8186838888 Fax: +91-8819-224168
E-mail : info.tnk@theandhrasugars.com
Website: www.theandhrasugars.com,
CIN : L15420AP1947PLC000326

From: Alice.Tsao@FDA.HHS.GOV <Alice.Tsao@FDA.HHS.GOV>
Sent: 01 November 2024 20:13
To: mktgaspirin@theandhrasugars.com
Subject: [WARNING: MESSAGE ENCRYPTED]USFDA - FMD 145 EIR - The Andhra Sugars Limited - 3003789475

11/01/2024
Mr. P.A. Ramayya, Joint Managing Director
The Andhra Sugars Limited
Venkatarayapuram West Godavari District Tanuku, Andhra Pradesh

Dear Mr. P.A. Ramayya, Joint Managing Director:

The U.S. Food and Drug Administration (FDA) conducted an inspection at The Andhra Sugars Limited, FEI 3003789475, located at Venkatarayapuram, West Godavari District, Tanuku, Andhra Pradesh, from 09/09/2024 to 09/13/2024. FDA has determined that the inspection classification of this facility is "no action indicated" ("NAI"). Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of NAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by the appropriate CDER or CVM review office. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact Alice S Tsao via telephone at 17186625657 or email at Alice.Tsao@FDA.HHS.GOV.

Sincerely,

Alice S Tsao
Regulatory Officer
PHARMACEUTICAL QUALITY I INVESTIGATION BRANCH II (PHRM1-IB2)

FDA U.S. FOOD & DRUG ADMINISTRATION

For THE ANDHRA SUGARS LIMITED

(P. V. S. VISWANADHA KUMAR)
Vice President (F) & Addl. Secretary